ANI Pharma to Snap Alimera Sciences Valuing The Target Company at $381M

6/24/24 6:55:27 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALIM alert in real time by email

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera") today announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera at approximately $381 million in up front consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024, as further described below.

Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with maintaining better vision longer. Alimera's two commercial products treat diabetic macular edema (DME) and chronic non-infectious uveitis affecting the posterior segment (NIU-PS) of the eye. ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) is indicated for DME in the U.S., Europe and the Middle East as well as for NIU-PS in Europe and the Middle East. YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) is available in the U.S. only and is indicated for the treatment of chronic NIU-PS.

Get the next $ALIM alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ALIM
$ANIP

Company	Date	Price Target	Rating	Analyst
ANI Pharmaceuticals Inc. $ANIP	7/10/2025	$84.00	Buy	H.C. Wainwright
ANI Pharmaceuticals Inc. $ANIP	3/14/2025	$80.00	Buy	Jefferies
ANI Pharmaceuticals Inc. $ANIP	3/12/2025	$85.00	Overweight	Analyst
ANI Pharmaceuticals Inc. $ANIP	12/11/2024	$80.00	Outperform	Leerink Partners
ANI Pharmaceuticals Inc. $ANIP	10/11/2024	$68.00	Overweight	Piper Sandler
Alimera Sciences Inc. $ALIM	6/25/2024		Buy → Neutral	H.C. Wainwright
Alimera Sciences Inc. $ALIM	3/25/2024	$10.00	Buy	Maxim Group
ANI Pharmaceuticals Inc. $ANIP	3/15/2024	$80.00	Overweight	CapitalOne

More analyst ratings

$ALIM
$ANIP
Press Releases

Fastest customizable press release news feed in the world

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited resultsProvides full year 2026 financial guidance, which includes: Total net revenues of $1,055 million to $1,115 millionCortrophin Gel net revenues of $540 million to $575 millionAdjusted non-GAAP EBITDA of $275 million t

1/12/26 6:50:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 30 days. About ANIANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by develo

1/6/26 4:15:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

ANI Pharmaceuticals Announces Formation of "FutureVision Advisory Council" to Help Strategically Guide Ophthalmology and Retina Franchise

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company's Rare Disease business. This steering committee includes seven retina specialists and three uveitis specialists recognized globally as leaders in their respective fields. "We have built a strong foundation for our ophthalmology and retina franchise and continue to look for opportunities to further positively impact patients," said Nikhil Lalwani, President and Chief Executive Officer of ANI. "Establi

12/2/25 6:50:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$ALIM
$ANIP
Leadership Updates

Live Leadership Updates

Alcami Announces CEO Transition

Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

1/13/25 11:12:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately. "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

12/12/23 7:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Alimera Appoints Maggie A. Pax to Its Board of Directors

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

11/8/23 4:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care